BerGenBio

Report Publication Announcement • Feb 20, 2019

BerGenBio ASA publishes Annual Report for 2018

BerGenBio ASA publishes Annual Report for 2018

Bergen, Norway, 20 February 2019 - The Board of Directors of BerGenBio ASA

(OSE:BGBIO) has today approved the Company's Annual Report for 2018 including

the complete 2018 Annual Accounts with notes. The report is attached and

available for download at www.bergenbio.com in the section: Investors/Financial

Reports.

-End-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

advanced and aggressive cancers.

The company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme. Ongoing clinical trials are investigating bemcentinib in multiple

solid and haematological tumours, in combination with current and emerging

therapies (including immunotherapies, targeted therapies and chemotherapy), and

as a single agent.

In parallel, BerGenBio is developing companion diagnostics test to identify

patient populations most likely to benefit from bemcentinib; this is expected to

facilitate more efficient registration trials and support a precision medicine

-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO).

www.bergenbio.com

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

International Media Relations

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic

Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.